NO20091662L - Nye antigener og antistoffer assosiert med pankreatisk, duktalt adenokarsinom - Google Patents

Nye antigener og antistoffer assosiert med pankreatisk, duktalt adenokarsinom

Info

Publication number
NO20091662L
NO20091662L NO20091662A NO20091662A NO20091662L NO 20091662 L NO20091662 L NO 20091662L NO 20091662 A NO20091662 A NO 20091662A NO 20091662 A NO20091662 A NO 20091662A NO 20091662 L NO20091662 L NO 20091662L
Authority
NO
Norway
Prior art keywords
antibodies
pda
ductal adenocarcinoma
pancreatic
identified
Prior art date
Application number
NO20091662A
Other languages
English (en)
Norwegian (no)
Inventor
Francesco Novelli
Barbara Tomaino
Paola Cappello
Original Assignee
Bioline Diagnostici Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioline Diagnostici Srl filed Critical Bioline Diagnostici Srl
Publication of NO20091662L publication Critical patent/NO20091662L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20091662A 2006-09-29 2009-04-27 Nye antigener og antistoffer assosiert med pankreatisk, duktalt adenokarsinom NO20091662L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06121552 2006-09-29
EP06126726 2006-12-20
PCT/EP2007/060305 WO2008037792A1 (en) 2006-09-29 2007-09-28 Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma

Publications (1)

Publication Number Publication Date
NO20091662L true NO20091662L (no) 2009-06-29

Family

ID=38895810

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091662A NO20091662L (no) 2006-09-29 2009-04-27 Nye antigener og antistoffer assosiert med pankreatisk, duktalt adenokarsinom

Country Status (18)

Country Link
US (1) US8071721B2 (https=)
EP (1) EP2069395B1 (https=)
JP (1) JP2010505104A (https=)
KR (1) KR20090094227A (https=)
CN (1) CN101578295B (https=)
AT (1) ATE542831T1 (https=)
AU (1) AU2007301966B2 (https=)
BR (1) BRPI0717282A2 (https=)
CA (1) CA2664841A1 (https=)
DK (1) DK2069395T3 (https=)
EA (1) EA016731B1 (https=)
ES (1) ES2381304T3 (https=)
IL (2) IL197868A (https=)
NO (1) NO20091662L (https=)
NZ (1) NZ576409A (https=)
PL (1) PL2069395T3 (https=)
PT (1) PT2069395E (https=)
WO (1) WO2008037792A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120003225A1 (en) * 2008-05-09 2012-01-05 Duke University Autoantibodies in the detection and treatment of cancer
IT1398782B1 (it) * 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
ITTO20120523A1 (it) * 2012-06-15 2013-12-16 Natimab Therapeutics S R L Procedimento e kit per la diagnosi in vitro dell'adenocarcinoma duttale pancreatico o per determinare la predisposizione all'adenocarcinoma duttale pancreatico
ES2729797T3 (es) * 2013-12-20 2019-11-06 Dev Ct Biotechnology Anticuerpos específicos de la alfa-enolasa y métodos de uso en terapias contra el cáncer
US10188708B2 (en) 2014-01-13 2019-01-29 Berg Llc Enolase 1 (Eno1) compositions and uses thereof
CN115786317B (zh) * 2022-12-12 2026-03-20 江苏三联生物工程股份有限公司 重组神经元特异性烯醇化酶及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753446A (en) * 1993-04-15 1998-05-19 National Jewish Center For Immunology & Respiratory Medicine Mitogen ERK kinase kinase (MEKK) assay

Also Published As

Publication number Publication date
US20100028907A1 (en) 2010-02-04
WO2008037792A1 (en) 2008-04-03
PL2069395T3 (pl) 2012-06-29
CA2664841A1 (en) 2008-04-03
EA200970332A1 (ru) 2009-10-30
BRPI0717282A2 (pt) 2013-10-15
ATE542831T1 (de) 2012-02-15
EA016731B1 (ru) 2012-07-30
NZ576409A (en) 2012-02-24
IL197868A0 (en) 2011-08-01
IL218442A0 (en) 2012-04-30
KR20090094227A (ko) 2009-09-04
EP2069395B1 (en) 2012-01-25
CN101578295A (zh) 2009-11-11
DK2069395T3 (da) 2012-05-14
PT2069395E (pt) 2012-04-27
AU2007301966B2 (en) 2013-02-21
AU2007301966A1 (en) 2008-04-03
ES2381304T3 (es) 2012-05-25
US8071721B2 (en) 2011-12-06
CN101578295B (zh) 2013-02-27
EP2069395A1 (en) 2009-06-17
IL197868A (en) 2013-03-24
JP2010505104A (ja) 2010-02-18

Similar Documents

Publication Publication Date Title
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
UA106771C2 (uk) Моноклональні антитіла до прогастрину та їх використання
NO20091662L (no) Nye antigener og antistoffer assosiert med pankreatisk, duktalt adenokarsinom
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EP1996716A4 (en) MANIPULATED ANTI-PROSTATE STEAM CELL RESPONSIVES (PSCA) ANTIBODIES FOR CANCER TARGETING
CY1119738T1 (el) Ανοσοσυζευγματα αντι-μεσοθηλινης και χρησεις αυτων
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
BRPI0808940A8 (pt) anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor
CY1116195T1 (el) Παραγοντες δεσμευσης του notch 1 υποδοχεα και μεθοδοι χρησης αυτων
PH12015500093A1 (en) Il-17 binding proteins
NO20083053L (no) Humane monoklonale antistoffer mot O8E
NO20073797L (no) Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA)
CY1117942T1 (el) Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
NO20090069L (no) Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse
JOP20180117B1 (ar) أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
ECSP12012272A (es) Proteínas que se unen al tnf-?
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
EA201070687A1 (ru) Способ ингибирования лейкозных стволовых клеток
UA95068C2 (uk) Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування
NO20092522L (no) Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
EA201001212A1 (ru) Лечение микробных инфекций
NO20084795L (no) Fremgangsmate for a behandle, diagnostisere eller detektere kreft

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application